
|Articles|September 6, 2013
VIDEO: Avoidable Costs in U.S. Healthcare
Doug Long, VP, Industry Relations, IMS Health, discusses the report: "Avoidable Costs in U.S. Healthcare: The $200 Billion Opportunity from Using Medicines More Responsibly."
Advertisement
Doug Long, VP, Industry Relations, IMS Health, discusses the report: "Avoidable Costs in U.S. Healthcare: The $200 Billion Opportunity from Using Medicines More Responsibly."
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
How the Delinking Model Can Drive Transparency, Avoid PBM Manipulation | NCPA 2025
2
PCV21 Shows Cost Effectiveness Compared With PCV15, PCV13, and PPSV23
3
Providers, Patients Show Favorable Perception of Remdesivir During COVID-19 Pandemic
4


























































































































































